The fear of hypodermic needles is universal. Whether for vaccine administration, blood glucose monitoring, or dermatological treatments, conventional sharp needles bring pain, bruising, and the risk of needlestick injuries-not to mention the environmental burden of biohazardous sharp waste. Today, we spotlight a transformative biomedical technology that is rewriting the rules: Microneedles (MNs).

Measuring merely 0.1–1 mm​ in length, these microscale arrays painlessly breach the skin's outermost barrier to deliver therapeutics or extract interstitial fluid (ISF) for non-invasive monitoring. From chronic disease management and wound repair to medical aesthetics and point-of-care testing (POCT), MNs are rapidly transitioning from research labs to commercial reality, emerging as one of the hottest R&D frontiers in the global biopharmaceutical industry.

Synthesizing global MN research up to 2021, this article presents a unified framework covering seven MN architectures, material trade-offs, nine mainstream fabrication methods, standardized mechanical testing, and four major application domains. We also highlight critical research gaps-scale-up manufacturing, long-acting release control, and material stability-to provide a comprehensive theoretical foundation for next-generation R&D in novel biomaterials, 3D printing, and wearable diagnostic devices.

Figure 1.​ Schematic illustration of transdermal mechanisms for seven types of microneedles.

1. What Are Microneedles? Seven Architectures, Seven Unique Logics

A microneedle array consists of hundreds to thousands of microscale needles arranged on a patch, with lengths strictly controlled to within 1 mm. By penetrating only the stratum corneum and epidermis-while completely avoiding the dermal nociceptors-MNs achieve truly minimally invasive, painless administration.

Based on structure, material, and mode of use, the industry classifies MNs into seven distinct types, each with a unique operational logic and application niche:

Materials & Geometry: MN materials span silicon, stainless steel, ceramics, synthetic polymers, and biodegradable biopolymers. Design dimensions typically range from 25–2500 μm in length​ and 1–25 μm in tip diameter. Common geometries include conical, pyramidal, and cylindrical profiles. Geometry is strategically tuned based on drug dose, skin mechanical properties, and detection requirements to ensure bend-free, fracture-free penetration.

Figure 2.​ Comparison of microneedle penetration depth versus conventional hypodermic injection.

2. Four Irreplaceable Advantages Over Injections and Topical Formulations

Traditional hypodermic injections and transdermal patches each have fundamental limitations. MNs bridge these gaps-here is why they are gaining unprecedented traction:

① Painless & Maximum Patient Compliance

Conventional needles penetrate the dermis, stimulating pain nerves-a major barrier for children and needle-phobic individuals. MNs confine penetration to the epidermis, producing only mild tactile sensation. Diabetic patients and those requiring frequent vaccinations can self-administer at home, drastically reducing clinical visits.

② Barrier Bypass & Superior Bioavailability

The stratum corneum blocks macromolecules-proteins, insulin, peptides, and antibiotics-from penetrating via topical creams. MNs create direct microchannels, enabling proteins, nucleic acids, and macromolecular drugs to reach target tissues​ with bioavailability far exceeding topical formulations, while completely bypassing gastrointestinal degradation and the first-pass hepatic effect.

③ Safety & Minimal Infection Risk

Dissolving and hydrogel MNs leave no sharp waste, eliminating needlestick injuries. The micro-wounds heal rapidly, with infection risk far lower than injections. Long-term use does not cause scarring or granulomas.

④ Dual-Function: Drug Delivery + Diagnostics

Many MN platforms achieve simultaneous drug delivery and ISF extraction-releasing hypoglycemic or anti-inflammatory drugs while sampling glucose, uric acid, or inflammatory markers in real time. This enables wearable closed-loop theranostic devices​ perfectly suited for long-term home-based chronic disease management.

3. Comprehensive Medical Applications: From Chronic Disease to Wound Care

3.1 Chronic Disease Transdermal Delivery - Goodbye Daily Injections

Diabetes management is the most mature MN application. Multiple insulin-loaded MNs and glucose-responsive smart MNs​ have entered clinical trials. Swellable and hydrogel MNs carrying insulin adjust release kinetics based on interstitial glucose levels, providing >12 hours of stable glycemic control​ from a single patch. Metformin-loaded hydrogel MNs enable prolonged sustained release, significantly reducing daily injection frequency.

For migraine and arthritis pain, ibuprofen and rizatriptan DMNs​ provide rapid local analgesia while avoiding gastrointestinal irritation associated with oral NSAIDs. Lidocaine MN patches​ deliver up to 8 hours of local anesthesia, suitable for pre-procedural epidermal analgesia and minimally invasive dermatological procedures.

Additionally, MNs enable localized antibiotic targeting. 3D-printed gelatin methacryloyl (GelMA) MNs loaded with amoxicillin act directly on infected skin sites, inhibiting S. aureusand E. coli, reducing systemic antibiotic exposure, and mitigating antimicrobial resistance.

3.2 Dermatology & Hair Regeneration

Topical minoxidil suffers from extremely poor transdermal penetration. Three-tier dissolving MNs​ deliver drugs directly to hair follicles-ex vivo studies show >3× higher follicular delivery​ compared to conventional creams. Curcumin and zinc-metal-organic framework (Zn-MOF) composite MNs further promote follicular regeneration while providing antioxidant and anti-inflammatory benefits.

For chronic wounds and diabetic ulcers, composite hydrogel MNs loaded with mesenchymal stem cell (MSC) exosomes, magnesium ions, and silver nanoparticles​ continuously release anti-inflammatory and pro-angiogenic factors, promoting M2 macrophage polarization and accelerating epithelial regeneration. Notably, algae-integrated dissolving MNs​ leverage photosynthetic oxygen generation to address hypoxia in diabetic wounds, dramatically shortening healing cycles.

3.3 Oncology & Localized Therapeutics - Precision with Minimal Systemic Toxicity

Conventional intravenous chemotherapy causes systemic damage. Dissolvable polysaccharide MNs​ enable local intratumoral delivery of antitumor agents, activating skin dendritic cells to initiate localized anti-tumor immunity. Mussel protein-adhesive MNs​ tightly conform to tumor surfaces for sustained local drug release at high concentrations, sparing hepatic and renal tissues from chemotherapy toxicity.

Furthermore, orally administered magnetically triggered MN capsules​ release drugs in the intestine for targeted local therapy of inflammatory bowel disease and parasitic infections-bypassing gastric acid degradation and achieving high local drug concentrations.

Figure 3.​ Overview of microneedle therapeutic applications across medical disciplines.

4. The Biosensing Boom: Non-Invasive Monitoring Without Blood Draws

4.1 Continuous Glucose Monitoring (CGM) - The Home-Care Imperative

Fingertip blood sampling is painful and provides only snapshot readings. Porous and colorimetric MN patches​ applied to the arm extract ISF, where glucose levels closely mirror blood concentrations. Gold nanozyme-based colorimetric MNs​ produce a visible color change upon glucose exposure-a smartphone photo converts the color signal into a quantitative glucose reading. Electrochemically modified MNs​ integrated with wearable circuits achieve 7-day real-time CGM​ with a 2-second response time and minimal error across the physiological glucose range.

4.2 Multi-Biomarker Synchronous Detection

ISF contains dozens of disease biomarkers-uric acid, lactate, renal proteins, psoriasis-associated miRNAs. Plasmonic MNs​ enable Raman spectroscopy-based trace uric acid detection for gout monitoring. Multi-layer electrochemical MNs​ simultaneously detect four renal biomarkers for at-home chronic kidney disease (CKD) follow-up. Functionalized gold MNs​ precisely monitor lactate for sports medicine and critical-care metabolic assessment. For inflammatory and autoimmune conditions, MNs extract skin ISF proteins for early screening-no venipuncture required.

4.3 Wearable Pressure & Oxygen Sensing

Beyond biochemical sensing, 3D-printed graphene-composite MNs​ function as flexible pressure sensors, conforming to the wrist to capture pulse waveforms with a 100 ms response time, covering the full physiological blood pressure range. Phosphorescent MN arrays​ measure cutaneous tissue oxygen partial pressure (pO2​) for peripheral circulation assessment and wound-healing monitoring-enabling at-home recovery tracking without repeated hospital visits.

Figure 4.​ Comprehensive schematic of microneedle-based biosensing scenarios.

5. How Are Microneedles Made? Nine Mainstream Fabrication Processes

MN fabrication directly determines needle hardness, precision, and production cost. The industry's nine dominant techniques are:

Figure 5.​ (A) 3D printing workflow for MNs; (B) Micro-molding preparation process.

Figure 6.​ Micro-molding techniques: (A) Vacuum & centrifugal methods; (B) Pressure & temperature methods.

6. Industry Landscape: High-Speed Growth Amid Unresolved Challenges

The global microneedle system market was valued at USD 2.65 billion in 2021, growing to USD 2.83 billion in 2022. Projections estimate the market will surpass USD 7.8 billion by 2027, representing a CAGR of 17.8%. Demand for minimally invasive medical devices and home-wearable health tech-particularly in the medical aesthetics segment-are the primary growth engines.

Persistent Technical Bottlenecks:

Brittleness: Silicon and metal MNs risk fracture and residual fragments causing inflammation.

Stability: Non-polymeric MNs are prone to oxidation and corrosion during long-term storage; temperature and humidity fluctuations degrade insertion force.

Scale-up Consistency: High-drug-loading MNs face challenges in maintaining batch-to-batch uniformity at industrial scale.

Current R&D Priorities​ focus on 3D-printed novel biomaterials, biodegradable composites, and smart stimuli-responsive MNs-optimizing crosslinking structures and molding processes to resolve stability and manufacturing challenges.

7. Conclusion: Microneedles Usher in a New Era of Painless Theranostics

From replacing hypodermic injections to enabling wearable non-invasive monitoring, microneedle technology has shattered the traditional barriers of drug delivery and diagnostics. Balancing comfort, efficacy, and safety, MNs now span chronic disease management, wound repair, medical aesthetics, POCT, and vaccine delivery.

As 3D printing, biodegradable materials, and flexible sensing technologies​ continue to evolve, we will witness a proliferation of consumer-ready MN patches. Patients with diabetes, gout, and chronic skin conditions will soon manage their health entirely from home-administering drugs and monitoring biomarkers without a single hospital visit.

This "black technology" - equally promising in clinical value and consumer potential - is poised to become a cornerstone of the future biomedical and wearable health device industries.